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Abstract
Background: Magnetic resonance cholangiopancreatography (MRCP) is an alternative to
diagnostic endoscopic retrograde cholangiopancreatography (ERCP) for investigating biliary
obstruction. The use of MRCP, a non-invasive procedure, may prevent the use of unnecessary
invasive procedures. The aim of the study was to compare the findings of MRCP with those of
ERCP by the computation of accuracy statistics.
Methods: Thirteen electronic bibliographic databases, covering biomedical, science, health
economics and grey literature were searched. A systematic review of studies comparing MRCP to
diagnostic ERCP in patients with suspected biliary obstruction was conducted. Sensitivity,
specificity, likelihood ratios, acceptability and adverse events were reported.
Results: 25 studies were identified reporting several conditions including choledocholithiasis (18
studies), malignancy (four studies), obstruction (three studies), stricture (two studies) and
dilatation (five studies). Three of the 18 studies reporting choledocholithiasis were excluded from
the analysis due to lack of data, or differences in study design. The sensitivity for the 15 studies of
choledocholithiasis ranged from 0.50 to 1.00 while specificity ranged from 0.83 to 1.00. The
positive likelihood ratio ranged: from 5.44–47.72 and the negative likelihood ratio for the 15 studies
ranged from 0.00–0.51. Significant heterogeneity was found across the 15 studies so the sensitivities
and specificities were summarised by a Receiver Operating Characteristic (ROC) curve. For
malignancy, sensitivity ranged from 0.81 to 0.94 and specificity from 0.92 to 1.00. Positive likelihood
ratios ranged from 10.12 to 43 and negative likelihood ratios ranged from 0.15 to 0.21, although
these estimates were less reliable.
Conclusion: MRCP is a comparable diagnostic investigation in comparison to ERCP for diagnosing
biliary obstruction.
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Biliary obstruction may be due to a variety of causes
including choledocholithiasis, tumours, and trauma,
including injury after gall bladder surgery, with choledo-
colithiasis being the most common cause. The prevalence
of gallstones in England and Wales was 182 per 10,000
person years at risk. The incidence rate was 8 per 10,000
person years at risk for 1991–1992 [1]. Patients with sus-
pected biliary obstruction present with abnormal liver
function and symptoms such as jaundice, pale-coloured
stools, dark urine, itching, abdominal pain in the upper
right quadrant, fever, nausea and vomiting. Endoscopic
ultrasonography (EUS) is the first-line imaging investiga-
tion in patients with jaundice or right upper-quadrant
pain [2]. Although EUS is non-invasive, quick and inex-
pensive it is very operator and patient dependent.
Endoscopic retrograde cholangiopancreatography (ERCP)
is currently the 'gold standard' for the diagnosis of biliary
obstruction. It is one of several invasive direct cholangiog-
raphy techniques. However, it is an imperfect diagnostic
tool and other procedures may be more appropriate gold
standards for diagnosis in the future [3]. Magnetic reso-
nance cholangiopancreatography (MRCP) is an alterna-
tive to diagnostic ERCP for imaging the biliary tree and
investigating biliary obstruction. MRCP was developed in
1991 and techniques are continuing to improve. A major
feature of MRCP is that it is not a therapeutic procedure,
while in contrast ERCP is used for both diagnosis and
treatment. MRCP also does not have the small but definite
morbidity and mortality associated with ERCP. The use of
MRCP in diagnosing biliary obstruction may avoid the
use of unnecessary invasive procedures such as ERCP.
Indications for the use of MRCP include: unsuccessful or
contraindicated ERCP; patient preference for non-invasive
imaging; patients considered to be at low risk of having
pancreatic or biliary disease; patients where the need for
therapeutic ERCP is considered unlikely; and those with a
suspected neoplastic cause for pancreatic or biliary
obstruction [4]. No patient preparation is required for
MRCP and sedation is not usually required. MRCP is par-
ticularly useful where ERCP is difficult, hazardous or
impossible. It is also an important option for patients
with failed ERCPs. ERCP and MRCP have different con-
traindications allowing them to be used as complemen-
tary techniques.
In order to determine the sensitivity and specificity of
MRCP compared to ERCP, a systematic review was under-
taken to identify all relevant studies comparing the two
techniques using clearly defined inclusion and exclusion
criteria. This paper therefore compares the findings of
MRCP with diagnostic ERCP for the investigation of bil-
iary obstruction, using accuracy statistics. We also report
study quality, population characteristics and suspected
conditions. The paper summarises the key clinical points
reported in a recent Health Technology Assessment Mon-
ograph [5]. Since the most common cause of biliary
obstruction is choledocholithiasis, we have concentrated
mainly on the diagnosis of this condition.
Methods
We searched 13 electronic databases Medline, Embase
and the Cochrane Controlled Trials Register from incep-
tion to January 2003. Reference lists of relevant articles
were hand searched and various health services research-
related resources were consulted via the Internet. Search
terms included population search terms such as biliary,
biliary tract, bile, gallbladder, choledocholithiasis and
were combined with intervention terms such as magnetic
resonance imaging, MRI and non-invasive diagnostic
imaging. The search strategy is described in detail else-
where [5]. No language or study/publication-type restric-
tions were applied to the searches. Inclusion criteria were
adult patients with suspected biliary obstruction or dilata-
tion, as defined by the individual studies, having MRCP
and ERCP for diagnostic purposes. Outcome measures
included sensitivity, specificity and likelihood ratios in
different patient groups, acceptability to patients and
adverse effects. The ERCP test results were assumed to be
a true 'gold standard' diagnosis, although even the results
of this test may be subject to error and thus not represent
the patient's true condition. Only English language papers
were selected. Studies involving pancreatic ductal system
abnormalities were excluded, as were those not including
a comparison of MRCP with diagnostic ERCP. Other
exclusion criteria were: papers published before 1995;
comparison of MRCP with failed or unsuccessful ERCP;
studies where MRCP results informed decision to proceed
to ERCP; and retrospective study design. Excluded studies
were documented together with reasons for exclusion [5].
Data was extracted by one researcher using a standardised
data extraction form and checked by another. Full details
of the review process are described elsewhere [5].
The studies were assessed using quality criteria for diag-
nostic or screening tests [6]. These criteria include 14 com-
ponents of study quality such as: appropriate spectrum of
patients, selection criteria, independent assessment of test
results, verification bias (whether all patients had both
tests), reporting of uninterpretable results and withdraw-
als among others.
Standard tests for heterogeneity were conducted [7]. Point
estimates and 95% confidence intervals for summary sta-
tistics (sensitivity, specificity, likelihood ratio) were calcu-
lated for each study and presented graphically with forest
plots. In meta-analyses of diagnostic results one must also
consider variation introduced by changes in the diagnos-Page 2 of 15
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define positive and negative test results. In the event of
heterogeneity and/or variation in the diagnostic thresh-
old, studies were summarised graphically with a Summary
Receiver Operating Characteristic curve (SROC) curve and
via the Littenberg and Moses (L-M) method for estimation
of a best fitting SROC curve [8]. The L-M method consists
of linear regression of the log diagnostic odds ratio, D,
against the log of the measure of diagnostic threshold S,
to produce estimates of the parameters a and b from the
regression equation, D = a + bS. D and S are calculated
from the true positive and false positive rates. We com-
puted the sensitivity and specificity values from the SROC
at the mean, minimum and maximum values of the S
parameter, to indicate a central value and associated band
with which the data were compatible.
Results
Out of a total of 1437 potentially relevant studies, 28
studies were identified that directly compared MRCP with
diagnostic ERCP [9-36]. An additional study was identi-
fied that covered patient satisfaction [37]. Study selection
is outlined in Figure 1. The quality of studies was variable.
Results are shown in Table 1.
In only one study did all selected patients have both
MRCP and diagnostic ERCP [31], indicating potential ver-
ification bias. Thirteen studies [10-12,14,15,17,18,25,28-
30,34,36] reported adequate blinding and only six
[10,18,22,27,29,34] reported information on agreement
of MRCP results for more than one investigator. Nine
studies [10,12,17,20,22,25,28,29,32] gave no informa-
tion on other diagnostic tests and most studies did not
adequately report inclusion and exclusion criteria.
Seven studies [9,17,21,22,25,26,34], reported results
comparing MRCP to final diagnosis (including ERCP and
other test results) but only four of these reported data
comparing MRCP with final diagnosis and ERCP with
final diagnosis. The remaining 21 reported results com-
paring MRCP with diagnostic ERCP. Three [10,17,19] of
the 28 studies did not provide enough information to cal-
culate sensitivity, specificity and likelihood ratios. Accu-
racy was assessed separately for each condition
(choledocolithiasis, malignancy, dilatation, obstruction
and stricture). The results of the remaining 25 studies are
shown in Table 2. Table 3 describes study characteristics.
Studies comparing MRCP and ERCP with final diagnosis
are shown in Table 4.
Assessment of effectiveness by condition: 
choledocolithiasis
One of the most common causes of biliary obstruction is
choledocolithiasis: indeed 18 out of the 28 studies (64%)
were for this condition. For this reason we concentrate
mainly on the analysis of these studies. Of the 18 studies
reporting results for choledocolithiasis, 15 [11,13-
15,18,20,21,26,27,29-31,33,35,36] reported adequate
data for analysis. Figure 2 shows a scatterplot of sensitivity
vs. specificity for the 15 studies reporting choledocholith-
iasis.
Two of these studies stand out as having sensitivities
somewhat lower than the other 13 studies [11,36]. Sensi-
tivities and specificities along with 95% CI for these esti-
mates for the 15 choledocholithiasis studies are presented
in Figures 3 and 4.
The sensitivity for the 15 studies of choledocholithiasis
ranged from 0.50 to 1.00 while specificity ranged from
0.83 to 1.00. The positive likelihood ratio ranged from
5.44–47.72 and the negative likelihood ratio for the 15
studies ranged from 0.00–0.51. All of the confidence
intervals overlap, although the confidence intervals for
some studies are wide. Again two studies [11,36] have
point estimates in Figure 2 that are clearly different from
the other 13 studies, suggesting that theses two studies are
outliers. There is also some evidence of statistically signif-
icant heterogeneity between studies, (Figure 3 and 4),
which suggested that the computation of a SROC curve
was the most appropriate way to pool the results of stud-
ies.
Summary ROC curves for diagnosis of choledocholithiasis
Figure 2 also shows the parameter estimates and the
results of the Littenberg-Moses method for the estimation
of a summary best fitting ROC curve. This curve shows the
relationship between sensitivities and specificities across
the 15 studies. The non-significant result for the S coeffi-
cient estimate of 0.057 [CI: -0.25 to 0.42; p = 0.506], sug-
gests that there is no reliable statistical evidence that the
diagnostic odds ratio changes with threshold.
There is no unique joint summary estimate of sensitivity
and specificity suitable for use in clinical practice from
this plot. Table 5 shows values of sensitivity and specifi-
city off the fitted ROC curve to demonstrate the range of
values that the data are compatible with.
Assessment of effectiveness by other conditions: 
malignancy, dilatation, obstruction and stricture
For malignancy (three studies [9,18,22]), sensitivity
ranged from 0.81 to 0.94 and specificity from 0.92 to
1.00. Positive likelihood ratios ranged from 10.12 to 43
and negative likelihood ratios ranged from 0.15 to 0.21.
Although, from the results presented in Table 2 it is appar-
ent that the results for malignancy are much less reliable
than those for the other conditions presented. The sensi-
tivity for dilatation (five studies [11,12,20,25,28]) ranged
from 0.87 to 1.00 and the specificity from 0.91 to 1.00.Page 3 of 15
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Summary of study selectionFigure 1
Summary of study selection.
Total
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N=311
Total full papers
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other sources) 
Included studies 
N=28 (plus 1 
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Studies
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Studies
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abstract
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Table 1: QUADAS quality assessment checklist applied to MRCP studies
Study 1. Patient 
spectrum
2. Selection 
criteria
3. Reference 
standard
4. Time 
period
5. Verification 
bias
6. Same 
RS
7. RS 
independent 
of IT
8. IT 
described 
in detail
9. RS 
described 
in detail
10. IT 
interpreted 
without RS
11. RS 
interpreted 
without IT
12. All 
clinical 
data
13. All 
test 
results
14. Withdrawals
Adamek[9] yes yes yes unclear no yes N/a yes no yes yes yes Yes yes
Angulo[11] yes yes unclear yes no yes N/a yes no yes yes no Yes yes
Barish[12] yes yes unclear yes no yes N/a yes no yes unclear no yes yes
Calvo[13] unclear yes unclear no no yes N/a yes unclear yes unclear yes Yes yes
Chan[14] yes unclear unclear yes no yes N/a yes unclear yes yes no Yes yes
Demartines [15] yes yes unclear unclear no yes N/a yes yes yes yes no no no
Dwerryhouse[16] unclear yes unclear no no yes N/a yes no unclear yes unclear Yes yes
Guibaud [18] yes yes unclear no no yes N/a yes no yes yes no Yes yes
Holzknecht[20] unclear yes unclear no no yes N/a yes yes yes yes unclear Yes yes
Laokpessi [21] no yes yes yes no yes N/a yes no yes unclear unclear Yes yes
Lee[22] yes yes yes no no yes N/a yes yes yes yes unclear No yes
Lomanto [23] yes unclear unclear unclear no yes N/a yes no unclear unclear unclear No no
Lomas[24] yes yes unclear yes no yes N/a yes yes no no yes Yes yes
Macaulay [25] yes unclear yes no no yes N/a yes no yes unclear no No no
Regan[26] yes unclear yes yes no yes N/a yes no yes unclear unclear Yes yes
Reinhold [27] yes yes unclear no no yes N/a yes no Yes unclear yes Yes yes
Soto 1996[28] no unclear unclear yes no yes N/a yes no Yes unclear no No unclear
Soto 2000b[29] yes yes unclear no no yes N/a yes unclear Yes yes no Yes yes
Soto 2000a[30] yes yes unclear no no yes N/a yes unclear Yes yes no Yes yes
Stiris[31] yes unclear unclear yes yes yes N/a yes no yes yes unclear Unclear unclear
Sugiyama[32] unclear no unclear no no yes N/a yes no no yes yes Yes yes
Taylor[33] yes yes unclear yes no yes N/a yes no Yes yes unclear Yes yes
Textor[34] yes unclear unclear no no yes N/a yes yes Yes unclear no Yes yes
Varghese [35] unclear unclear unclear no no yes N/a yes yes yes yes yes Yes yes
Zidi[36] yes no unclear yes no yes N/a yes yes Yes unclear no No no
RS = reference standard (ERCP); IT = index test (MRCP).
QUADAS Questions
1. Was the spectrum of patients representative of the patients who will receive the test in practice?
2. Were selection criteria clearly described?
3. Is the reference standard likely to correctly classify the target condition?
4. Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests?
5. Did the whole sample or a random selection of the sample, receive verification using a reference standard of diagnosis?
6. Did patients receive the same reference standard regardless of the index test result?
7. Was the reference standard independent of the index test (i.e. the index test did not form part of the reference standard?
8. Was the execution of the index test described in sufficient detail to permit replication of the test?
9. Was the execution of the reference standard described in sufficient detail to permit its replication?
10. Were the index test results interpreted without knowledge of the results of the reference standard?
11. Were the reference standard results interpreted without knowledge of the results of the index test?
12. Were the same clinical data available when test results were interpreted as would be available when the test is used in practice?
13. Were uninterpretable/intermediate test results reported?
14. Were withdrawals from the study explained?
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Table 2: The 25 included studies
Study Total 
number Of 
patients
Suspected 
Condition
True +ve False +ve False -ve True -ve N Sensitivity 
(95% CI)
Specificity 
(95% CI)
Likelihood ratio-
positive (95% CI)
Likelihood 
ratio-negative 
(95% CI)*
Adamek[9] 86 Abnormality 42 1 5 12 60 0.89 (0.77, 0.95) 0.92 (0.67, 0.99) 11.62 (1.76, 76.57) 0.12 (0.02, 0.76)
Adamek 81 Malignancy 22 0 5 33 60 0.81 (0.63, 0.92) 1.00 (0.90, 1.00) 54.64 (3.47, 861.18) 0.20 (0.01, 3.14)
Angulo[11] 73 Normal 19 2 3 46 70 0.86 (0.67, 0.95) 0.96 (0.86, 0.99) 20.73 (5.28, 81.31) 0.14 (0.04, 0.56)
Angulo 70 dilitation CBD 38 2 3 27 70 0.93 (0.81, 0.97) 0.93 (0.78, 0.98) 13.44 (3.52, 51.33) 0.08 (0.02, 0.30)
Angulo 72 Obstruction 37 3 0 39 79 1.00 (0.91, 1.00) 0.91 (0.76, 0.97) 11.00 (3.74, 32.36) 0.00
Angulo 70 Choledocholithiasis 5 1 5 59 70 0.50 (0.24, 0.76) 0.98 (0.91, 1.00) 30.00 (3.90, 230.73) 0.51 (0.07, 3.91)
Angulo 70 PSC 19 1 4 46 70 0.83 (0.63, 0.93) 0.98 (0.89, 1.00) 38.83 (5.53, 272.37) 0.18 (0.03, 1.25)
Barish[12] 29 Dilitation 13 0 2 6 21 0.87 (0.62, 0.96) 1.00 (0.61, 1.00) 11.81 (0.81, 172.17) 0.17 (0.01, 2.45)
Calvo[13] 61 Choledocholithiasis 29 2 3 10 44 0.91 (0.76, 0.97) 0.83 (0.55, 0.95) 5.44 (1.53, 19.36) 0.11 (0.03, 0.40)
Chan[14] 47 Choledocholithiasis 18 4 1 22 45 0.95 (0.75, 0.99) 0.85 (0.66, 0.94) 6.16 (2.48, 15.26) 0.06 (0.03, 0.15)
Demartines[15] 40 Choledocholithiasis 19 2 0 19 40 1.00 (0.83, 1.00) 0.90 (0.71, 0.97) 10.50 (2.81, 39.24) 0.00
Dwerryhouse[16] 40 Choledocholithiasis 7 2 1 28 38 0.88 (0.53, 0.98) 0.93 (0.79, 0.98) 13.13 (3.35, 51.36) 0.1 (0.03, 0.52)
Guibaud[18] 79 Obstruction 72 0 7 47 126 0.91 (0.83, 0.96) 1.00 (0.92, 1.00) 87.00 (5.52, 1372.23) 0.09 (0.01, 1.49)
Guibaud Choledocholithiasis 26 2 6 92 126 0.81 (0.65, 0.91) 0.98 (0.93, 0.99) 38.19 (9.60, 151.97) 0.19 (0.05, 0.76)
Guibaud Malignancy 12 2 2 110 126 0.86 (0.60, 0.96) 0.98 (0.94, 1.00) 48.00 (11.96, 192.72) 0.15 (0.04, 0.58)
Holzknecht[20] 61 Choledocholithiasis 12 3 2 46 63 0.86 (0.60, 0.96) 0.94 (0.83, 0.98) 14.00 (4.58, 42.78) 0.15 (0.05, 0.47)
Holzknecht Dilatation 32 2 2 26 62 0.94 (0.81, 0.98) 0.93 (0.77, 0.98) 13.18 (3.46, 50.23) 0.06 (0.02, 0.24)
Holzknecht Stenosis 31 3 5 22 61 0.86 (0.71, 0.94) 0.88 (0.70, 0.96) 7.18 (2.46, 20.91) 0.16 (0.05, 0.46)
Holzknecht Overall 43 3 4 12 62 0.91 (0.80, 0.97) 0.80 (0.55, 0.93) 4.57 (1.66, 12.63) 0.11 (0.04, 0.29)
Laokpessi[21] 101 Choledocholithiasis 105 0 8 34 147 0.93 (0.87, 0.96) 1.00 (0.90, 1.00) 64.78 (4.13, 1015.86) 0.08 (0.00, 1.19)
Lee[22] 46 Malignancy 17 2 4 23 46 0.81 (0.60, 0.92) 0.92 (0.75, 0.98) 10.12 (2.64, 38.86) 0.21 (0.05, 0.79)
Lomanto[23] 136 Choledocholithiasis 22 0 2 38 62 0.92 (0.74, 0.98) 1.00 (0.91, 1.00) 70.20 (4.46, 1105.97) 0.10 (0.01, 1.60)
Lomas[24] 76 Choledocholithiasis 9 2 0 58 69 1.00 (0.70, 1.00) 0.97 (0.89, 0.99) 30.00 (7.68, 117.19) 0.00
Lomas Stricture 19 1 0 49 69 1.00 (0.83, 1.00) 0.98 (0.90, 1.00) 50.00 (7.18, 348.04) 0.00
Macaulay[25] 29 Dilatation 18 1 0 10 29 1.00 (0.82, 1.00) 0.91 (0.62, 0.98) 11.00 (1.70, 71.28) 0.00
Regan[26] 23 Choledocholithiasis 14 1 1 7 23 0.93 (0.70, 0.99) 0.88 (0.53, 0.98) 7.47 (1.19, 46.94) 0.08 (0.01, 0.48)
Reinhold[27] 110 Obstruction 69 0 7 34 110 0.91 (0.82, 0.95) 1.00 (0.90, 1.00) 63.18 (4.03, 991.27) 0.10 (0.01, 1.55)
Reinhold Choledocholithiasis 27 3 3 77 110 0.90 (0.74, 0.97) 0.96 (0.90, 0.99) 24.00 (7.86, 73.31) 0.10 (0.03, 0.32)
Soto 1996[28] 46 Dilatation 26 1 1 16 44 0.96 (0.82, 0.99) 0.94 (0.73, 0.99) 16.37 (2.44, 109.77) 0.04 (0.01, 0.26)
Soto 2000[29] 57 Choledocholithiasis 23 1 1 24 49 0.96 (0.80, 0.99) 0.96 (0.80, 0.99) 23.96 (3.50, 163.78) 0.04 (0.01, 0.30)
Soto 2000[30] 51 Choledocholithiasis 25 0 1 25 51 0.96 (0.81, 0.99) 1.00 (0.87, 1.00) 49.11 (3.15, 765.62) 0.06 (0.00, 0.88)
Stiris[31] 50 Choledocholithiasis 28 1 4 17 50 0.88 (0.72, 0.95) 0.94 (0.74, 0.99) 15.75 (2.33, 106.28) 0.13 (0.02, 0.89)
Sugiyama[32] 159 anamalous PBJ 9 0 2 148 159 0.82 (0.52, 0.95) 1.00 (0.97, 1.00) 235.92 (14.60, 3811.82) 0.21 (0.01, 3.38)
Taylor[33] 146 Choledocholithiasis 45 9 1 74 129 0.98 (0.89, 1.00) 0.89 (0.81, 0.94) 9.02 (4.86, 16.74) 0.02 (0.01, 0.05)
Taylor Stricture 12 1 0 118 131 1.00 (0.76, 1.00) 0.99 (0.95, 1.00) 118.00 (16.76, 830.78) 0.00
Textor[34] 150 PSC 29 1 4 108 142 0.88 (0.73, 0.95) 0.99 (0.95, 1.00) 95.79 (13.56, 676.70) 0.12 (0.02, 0.86)
Varghese[35] 191 Choledocholithiasis 31 3 3 154 191 0.91 (0.77, 0.97) 0.98 (0.95, 0.99) 47.72 (15.48, 147.06) 0.09 (0.03, 0.28)
Zidi[36] 70 Choledocholithiasis 28 0 21 21 70 0.57 (0.43, 0.70) 1.00 (0.85, 1.00) 25.08 (1.60, 392.61) 0.44 (0.03, 6.89)
* With likelihood ratios of zero, the data are unsuitable for the calculation of 95% confidence intervals.
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cases and more than 1 week in 
six cases
d because of 
P leaving 61 
June 1995 to 
MRCP performed before ERCP 
(patients were due to have ERCP 
within the next 2 days)B
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Table 3: Study characteristics
Study, country Sample selection Comparison (type of MRCP and 
reference tests used)
Description of patients and procedu
period
Adamek et al, 1998; 
Germany[9]
Not reported RARE and HASTE MRCP were compared 
with ERCP
86 patients entered the study; 8 were ex
to biliary-enteric anastomoses, of the rem
16 had unsatisfactory ERCP, 2 had unsati
MRCP (claustrophobia) leaving 60 patien
both January-December 1996
Angulo et al, 2000; USA[11] Not reported Fast spin echo pulse sequence compared 
with ERCP and PTC
Initially 74, 1 did not receive MRCP due t
claustrophobia, 73 had MRCP, 68 had ER
PTC and 3 had neither Study period not 
Barish et al, 1995; USA[12] Random selection from 
referrals
3D TSE MRCP compared with ERCP and 
PTC
30 patients initially selected, one patient 
receive MRCP due to the presence of as
the upper abdomen; three had PTC due 
ERCP, 8 of the 29 patients did not have E
Study period not reported
Calvo et al, 2002; Spain[13] Not reported Two HASTE sequences MRCP compared 
with ERCP
116 patients with suspected biliopancreat
initially, of these 61 patients were selecte
suspected choledocholithiasis, failure in o
for ERCP November 1996-February 199
Chan et al, 1996; Hong 
Kong[14]
Consecutive sample T2-weighted turbo spin-echo sequence 
(non-breath-hold, fat-suppressed) MRCP 
compared with ERCP
47 had MRCP, 45 had ERCP (two failures
August 1995
Demartines et al, 2000; 
Switzerland[15]
Not reported 3 acquisition techniques of MRCP were 
used including T2/T1 weighted, single-shot 
turbo spin echo and half-Fourier 
acquisition single-shot turbo spin echo 
heavy sequence compared with ERCP 
(high-risk patients) or intraoperative 
cholangiography (moderate risk patients)
40 patients received ERCP and MRCP an
received IOC and MRCP April 1997-Sept
Dwerryhouse et al, 1998; 
UK[16]
Not reported T2 weighted TSE with non-breath-holding 
MRCP compared with ERCP and POC
Initially 405 patients who underwent lapa
cholecystectomy, of these 278 had no kn
factors for CB stones, 87 underwent ear
were excluded. 40 patients with risk fact
stones underwent MRCP. 2 patients had 
due to claustrophobia, ERCP was unsucc
patients who then had peroperative chol
February 1996 – January 1998
Guibaud et al, 1995; 
Canada[18]
Consecutive 2D FSE MRCP compared with ERCP, 
PTC, T-tube cholangiography, surgery and 
autopsy
198 patients initially of which 72 were ex
to no proof of bile duct obstruction (n =
unsuccessful ERCP (n = 12), unsuccessful
to claustrophobia (n = 6), inadequate ER
or MRCP (n = 2) leaving 126 patients Sep
1992-March 1993
Holzknecht et al, 1998; 
Germany[20]
Consecutive sample RARE and half-Fourier RARE MRCP 
compared with ERCP
66 patients were eligible, 2 were exclude
pacemakers, 3 had failed ERCP after MRC
patients who had both MRCP and ERCP 
April 1996
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from study 
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excessive 
n = 7) 
Average time between MRCP 
and final diagnosis 10 hours 
(range 3–48 hours) if longer than 
48 hours between MRCP and 
final diagnosis, patients were 
removed from the study
 because 
valuated for 
 of 
cted 
leaving 46 
January-
33 patients had MRCP before 
ERCP ranging from 6 hours to 5 
days. The remaining 31 patients 
had ERCP first ranging from 3 to 
16 days
 62 had 
 74 were: 48 
revious 
nostomy and 
patients had 
ctober 1995
Not reported
P (one was 
 not have 
 the 
mmon bile 
8 month 
MRCP took place first within 4 
hours of ERCP
s had 28 
RCP, 6 had 
ported.
ERCP took place within 1–4 
hours in 15 patients, 4 were 
within 5–7 days after MRCP and 
1 was 11 days before and 
another 109 days before MRCP, 
all PTC studies were within 2 
days after MRCP and the 1 IOC 
preceded MRCP by 5 days.
 one did not 
g 23 patients
MRCP was performed just 
before ERCP in 18 patients and 
within 24 hours in 5 patients
cluded due 
f diagnosis, 
nsuccessful 
 ERCP (n = 
10 patients. 
had surgery. 
d
MRCP was performed first and 
ERP or equivalent was less than 6 
hours later in 97 patients, less 
than 1 week in 7 patients and 
more than 1 week in 6 patients
Barish et al, 
 1994-April 
ERCP/PTC within 24 hours after 
MRCPB
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Laokpessi et al, 2001; 
France[21]
Consecutive sample FSE and T2 heavily weighted single-shot 
FSE sequences with fat suppression MRCP 
compared with ERCP or intraoperative 
cholangiography (IOC)
Initially 166 inpatients but only 147 patien
MRCP, of these 101 had ERCP and 45 ha
cholecystectomy. Those in group receivin
a past history of cholecystectomy or had
surgical or anaesthetic risk. 21 removed 
for: refusal to sign protocol (n = 3), refus
undergo MRCP (n = 4) or ERCP (n = 7), 
time between MRCP and final diagnosis (
November 1997-December 1999
Lee et al, 1997; South 
Korea[22]
Consecutive sample 3D steady-state free-precession MRCP 
compared with ERCP
71 patients of which 25 were excluded (8
ERCP was not performed, 15 who were e
intrahepatic stones, 1 for peripheral type
intrahepatic cholangiocarcinoma, 1 suspe
mucinous ductal ectasia of the pancreas) 
patients who had both MRCP and ERCP 
March 1995
Lomanto et al, 1997; Italy[23] Not reported T2 weighted TSE sequence MRCP 
compared with ERCP and PTC
136 patients referred for MRCP, of these
MRCP for choledocholithiasis, (the other
for stenosis of the biliary tract, 15 with p
hepaticojejunostomy and choledochojeju
11 with chronic pancreatitis) 60 of these 
ERCP and 2 had PTC September 1994-O
Lomas et al, 1999; UK[24] Not reported Hybrid four-shot RARE (FSE) sequence 
and a single-shot half Fourier RARE 
sequence compared with ERCP
76 referrals, of these 2 did not have MRC
obese and one was claustrophobic), 5 did
ERCP (1 died, 1 refused and in 3 patients
operator was unable to cannulate the co
duct) leaving 69 referrals in 66 patients 1
period, dates not stated
Macaulay, et al, 1995; 
USA[25]
Sequential T2-weighted TSE MRCP (non-breath 
hold) compared with ERCP, PTC and IOC
28 patients initially had MRCP, 24 patient
direct cholangiographic studies (21 had E
PTC and 1 had IOC) Study period not re
Regan et al, 1996; USA[26] Not reported HASTE MRCP compared with ERCP and 
sonography
26 patients, 2 had unsuccessful ERCP and
have MRCP due to claustrophobia leavin
Reinhold et al, 1998; 
Canada[27]
Consecutive FSE MRCP compared with ERCP, IOC and 
surgery
Initially 159 patients of which 49 were ex
to the following reasons: 34 due to lack o
10 due to unsuccessful ERCP, 3 due to u
MRCP due to claustrophobia, inadequate
1) or MRCP (n = 1) leaving a sample of 1
101 patients had ERCP, 2 had IOC and 7 
5 month study period, dates not reporte
Soto et al, 1996; USA[28] Randomly recruited 3D FSE MRCP compared with ERCP and 
PTC
46 patients, 7 of whom were included in 
199558, 45 had ERCP and 1 had PTC May
1995
Table 3: Study characteristics (Continued)
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icted June 
MRCP was 0 to 14 days before 
ERCP
RCP 
nd in 1 
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ad PTC and 
d MRCP 
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ovember 
MRCP was performed within 24 
hours before ERCP
ccessful 
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nastomosis 
ERCP was performed 1–14 days 
before MRCP (mean 3.2 days)
cluded 
copy images 
giography 
 22), MRCP 
(n = 5), 
ality (n = 7), 
 
= 29), IOC 
d, dates not 
MRCP was performed before 
ERCP within a period of 4 hours 
to 2 weeks (mean 18 hours)
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hours before ERCPB
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Soto et al, 2000a; 
Columbia[30]
Not reported Breath hold, single shot half-Fourier rapid 
acquisition and non-breath-hold 3D FSE 
MRCP compared with ERCP, CT and 
oral-contrast enhanced CT 
cholangiography
Initially 68 patients, 12 did not meet inclu
exclusion criteria, 2 did not have MRCP 
claustrophobia, in 3 ERCP was not attem
completed leaving 51 patients who had a
April 1998-March 1999
Soto et al, 2000b; 
Columbia[29]
Not reported 3D fast SE, Single section Half-Fourier 
RARE and multi-section half-Fourier 
RARE MRCP compared with ERCP
Initially 59 patients, 10 were excluded du
following reasons: 2 due to MRCP contra
4 because 1 or more of the 3 MRCP sequ
not be completed, and 4 because ERCP c
completed August 1997-May 1998
Stiris et al, 2000; Norway[31] Consecutive sample HASTE fat suppressed breath-hold MRCP 
compared with ERCP
50; all patients had both techniques; stud
stated
Sugiyama et al, 1998; 
Japan[32]
Non consecutive HASTE MRCP compared with ERCP 187 patients were recruited, 19 underwe
cholangiography or pancreatography on E
the common channel could not be identi
and there was failure of cannulation in 2 
leaving 159 patients with common bile du
pancreatic duct and common channel dep
1994-August 1996
Taylor et al, 2002; 
Australia[33]
Consecutive sample HASTE MRCP compared with ERCP, PTC 
or surgery
Initially 149 procedures (146 patients), M
unsuccessful in 8 due to claustrophobia a
patient due to poor image quality, 5 were
because MRCP was more than 24 hours 
ERCP, in 20 ERCP was unsuccessful (3 ha
subsequent ERCP, 2 had surgery and 2 h
were included). In two patients ERCP an
were both unsuccessful, leaving 129 patie
both MRCP and ERCP (or equivalent). N
1998-December 1999
Textor et al, 2002; 
Germany[34]
Consecutive sample 3D T2 weighted FSE MRCP compared 
with ERCP
150 patients initially, of which 146 had su
MRCP, 3 patients with PSC had unsucces
and another failed due to a bilidigestive a
January 1996-December 2000
Varghese et al, 2000; 
Ireland[35]
Consecutive sample T2 weighted 2D multi-slice FSE MRCP 
compared with ERCP, PTC or IOC
256 patients initially, 64 of which were ex
because ultrasound report or ERCP hard-
were not available (n = 30), direct cholan
was not performed after failed ERCP (n =
not performed due to contraindications 
MRCP images were of non-diagnostic qu
resulting in 191 patients [of these 34 had
choledocolithiasis diagnosed by ERCP (n 
(n = 3) and PTC (n = 2)] 18 month perio
stated
Zidi et al, 1999; France[36] Consecutive sample Non breath-hold fat suppressed TSE 
MRCP compared with ERCP (with or 
without sphincterotomy), 
endosonography or IOC
70 inpatients were included, 63 had ERC
sonography and 2 had IOC 12 month per
not reported
Table 3: Study characteristics (Continued)
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Scatterplot of sensitivity vs. 1-specificity of MRCP test for diagnosing choledocholithiasis with Littenberg-Moses Summary ROC curve and actual da a (n = 15 tud es)Figure 2
Scatterplot of sensitivity vs. 1-specificity of MRCP test for diagnosing choledocholithiasis with Littenberg-Moses Summary ROC 
curve and actual data (n = 15 studies).
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15  Zidi [36]
BMC Medical Imaging 2006, 6:9 http://www.biomedcentral.com/1471-2342/6/9For obstruction (three studies [11,18,27]), sensitivity
ranged from 0.91 to 1.00 and specificity from 0.91 to
1.00. Sensitivity for stricture (two studies [24,33]) was
1.00 and specificity ranged from 0.98 to 0.99.
Adverse events and satisfaction with procedures
None of the 28 studies reported any adverse events associ-
ated with MRCP. Six studies [9,11,13,27,31,34] reported
adverse effects associated with ERCP, including pancreati-
tis, bleeding and pain. Two [10,15] reported that no
adverse events had occurred and 20 gave no information
at all regarding adverse events. Claustrophobia associated
with MRCP was reported in ten studies
[9,11,16,18,19,24,26,27,30,33].
The separate study [37] dealing with patient satisfaction
found that most patients preferred MRCP, although there
were still some patients who preferred ERCP. Almost half
of the patients in this small study complained of claustro-
phobia associated with MRCP, although very few (5.9%)
refused MRCP for this reason.
Discussion
This systematic review shows that there is evidence that
MRCP stands up well to comparisons with diagnostic
Forest plot of estimated sensitivities of MRCP test for diagnosing choledocholithiasis (n = 15 studies)igure 3
Forest plot of estimated sensitivities of MRCP test for diagnosing choledocholithiasis (n = 15 studies).
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BMC Medical Imaging 2006, 6:9 http://www.biomedcentral.com/1471-2342/6/9ERCP, for the diagnosis of many biliary abnormalities.
From the small number of comparative studies with final
diagnosis, it appears that ERCP is an adequate reference
standard for choledocholithiasis with sensitivities and
specificities above 89%, however the results for malig-
nancy were much less reliable. The limited evidence on
patient satisfaction shows that patients prefer MRCP to
diagnostic ERCP. The results of our review are similar to
those found by Romagnuolo et al [38] who in their meta-
analysis showed high levels of sensitivity and specificity
for demonstrating the level and presence of biliary
obstruction.
The main advantage of MRCP is that diagnostic ERCP may
be associated with significant morbidity and mortality
[39]. Reported complication rates of diagnostic ERCP are
Forest plot of estimated specificities of MRCP test for diagnosing choledocholithiasis (n = 15 studies)igure 4
Forest plot of estimated specificities of MRCP test for diagnosing choledocholithiasis (n = 15 studies).
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BMC Medical Imaging 2006, 6:9 http://www.biomedcentral.com/1471-2342/6/95–6% and mortality figures range from 0.01% (36) to
0.89% [40]. Therapeutic ERCP has a complication rate of
4–10% [41]. Diagnostic ERCP has the potential to allow a
therapeutic procedure to be performed immediately, but
its indiscriminate use will result in an increasing propor-
tion of patients in whom such intervention is found to be
unnecessary. If preliminary tests, such as EUS or com-
puted tomography, clearly indicate the need for therapeu-
tic ERCP, then the use of diagnostic MRCP is probably
unwarranted. Those patients with a high probability of
choledocholethiasis on the basis of EUS investigations
usually proceed directly to ERCP. These issues are elabo-
rated in Bravo et al [42].
There were no reported adverse events associated with
MRCP, other than claustrophobia. However, in certain cir-
cumstances MRCP cannot be performed due to contrain-
dications to Magnetic Resonance Imaging, e.g. in patients
with cardiac pacemakers or cochlear implants. Severe
claustrophobia may make patients intolerant of the proce-
dure.
Limitations of this study
Overall the quality of the studies was variable. In only one
study did all selected patients have both MRCP and diag-
nostic ERCP. The reasons why all patients in the other
studies did not receive both investigations were not clear.
In 21 of the studies, the stated comparison was with
ERCP, while in the other seven studies, comparison was
with final diagnosis; making comparisons between all
studies difficult.
We can consider three ways of categorising a patient: their
true condition, the diagnosis and the test results [43]. We
have calculated the sensitivity and specificity of MRCP in
relationship to diagnosis by ERCP, but we do not neces-
sarily know that the diagnosis is always correct. ERCP is
not a perfect gold standard, so differences in diagnosis
between MRCP and ERCP may not be due to MRCP giving
an incorrect result, but rather to ERCP giving an incorrect
result. So we have evaluated MRCP's ability to predict the
diagnosis of choledocholithiasis rather than the patient's
true disease status. So any errors in the ERCP reference test
may lead to either underestimates or overestimates of
MRCP's accuracy.
There are several problems associated with using sum-
mary ROC curves. For example, although the production
of a summary ROC curve does allow the computation of
a summary estimate of diagnostic performance, the results
cannot be directly applied to clinical practice.
Our results indicate that MRCP is accurate for diagnosis of
biliary abnormalities compared to diagnostic ERCP,
within the limits of the available data. Good quality stud-
Table 5: Estimates of diagnostic odds ratio (DOR), sensitivity and 
specificity from the regression of D = a + bS for Littenberg-Moses 
Summary ROC curve for MRCP test diagnosis of 
choledocholithiasis (n = 15 studies) for a range of values of 
diagnostic threshold (S)
Diagnostic Odds 
Ratio (DOR)
Sensitivity Specificity
mean S 193.22 0.91 0.95
min S 144.79 0.61 0.99
max S 239.34 0.97 0.87
Table 4: Studies comparing MRCP and ERCP with final diagnosis
Study Definition of Final 
diagnosis
Sensitivity Specificity
MRCP vs. final 
diagnosis
ERCP vs. final 
diagnosis*
MRCP vs. final 
diagnosis
ERCP vs. final 
diagnosis*
Adamek[9] ERCP plus histological 
findings or follow-up
42/47 for any 
abnormality
0.89 (CI: 0.77–0.95)
22/27 for malignancy
0.81 (CI: 0.63–0.92)
0.91 for any 
abnormality
0.93 for malignancy
12/13
0.92 (CI: 0.67–0.99) for 
any abnormality
33/33
1.00 (CI: 0.90–1.00) for 
malignancy
0.92 for any 
abnormality
0.94 for malignancy
Laokpessi[21] Stone extraction with 
ERCP or IOC
105/113
0.93 (CI: 87–0.96) for 
Choledocholithiasis
78/81
0.95 (CI: 0.87–0.98)
34/34
1.00 (CI: 0.90–1.00)
19/19
1.00 (CI: 0.79–1.00)
Lee[22] ERCP plus surgical findings 17/21 for malignancy
0.81 (CI: 0.60–0.92)
15/21
0.71 (CI: 0.50–0.86)
23/25
0.92 (CI: 0.75–0.98)
23/24
0.96 (CI: 0.80 to 0.99)
Regan[26] ERCP, endoscopic balloon 
or basket extraction or 
surgical removal of stones
14/15
0.93 (CI: 0.70–0.99) 
for choledocholithiasis
15/15
1.00 (CI: 0.80–1.00)
7/8
0.88 (CI: 0.53–0.98)
8/8
1.00 (CI: 0.68–1.00)
*Raw data was not reported in some studies, therefore it is not clear whether are not the two groups (MRCP vs. final diagnosis and ERCP vs. final 
diagnosis) are directly comparable.Page 13 of 15
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BMC Medical Imaging 2006, 6:9 http://www.biomedcentral.com/1471-2342/6/9ies, particularly randomised controlled trials (we found
no comparative clinical trials of the two techniques in our
review), are needed comparing MRCP with diagnostic
ERCP to final diagnosis, stating inclusion/exclusion crite-
ria and relevant patient characteristics. These studies need
to include the full range of target conditions, in particular
the differentiation of benign and malignant strictures and
the impact on management and outcome. Studies are also
needed comparing MRCP with final diagnosis where
ERCP is unsuitable or impossible. More research is also
needed in the area of patient satisfaction and ways to
reduce problems with claustrophobia.
Conclusion
MRCP is a comparable diagnostic investigation in com-
parison to ERCP for diagnosing biliary abnormalities.
Results were particularly favourable for choledocholethia-
sis and less so for malignancy. Limited information on
patient satisfaction found that patients prefer MRCP to
ERCP. The use of MRCP in suitable patients reduces the
need for diagnostic ERCP which is associated with signif-
icant morbidity and mortality.
Abbreviations
DOR diagnostic odds ratio
ERCP endoscopic retrograde cholangiopancreatography
L-M Littenberg and Moses
MRCP magnetic resonance cholangiopancreatography
ROC Receiver Operating Characteristic curve
SROC Summary Receiver Operating Characteristic curve
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